CHROMIUM X CELL ANALYZER, CHROMIUM NEXT GEM KITS, BRAND NAME OR EQUAL

This notice is a combined synopsis/solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 - Streamlined Procedures for Evaluation and solicitation for commercial Items, as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation (a written solicitation will not be issued) and quotes are being requested. The Solicitation number is RFQ-NIAID-2134590 and the solicitation is issued as a Request for Quotes (RFQ). This acquisition will be processed under FAR Part 13 Simplified Acquisition Procedures (SAP). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular FAC 2022-06 Effective May 26, 2022 The North American Industry Classification System (NAICS) code for this procurement is 325413 - In-Vitro Diagnostic Substance Manufacturing with a size standard of 1250 employees. The requirement is being competed with a Brand Name or Equal Restriction, and with a Small Business Set-aside. The National Institute of Allergy and Infectious Diseases (NIAID) has a requirement for the brand name products manufactured by 10X Genomics: 1) Chromium Next GEM Single Cell 5' Kit v2, 16 rxns CAT # 1000263 QTY: 3 2) Chromium Next GEM Chip K Single Cell Kit, 48 rxns CATALOG # 1000286 QTY: 1 3) 5' Feature Barcode Kit, 16 rxns CATALOG # 1000256 QTY: 3 4) Library Construction Kit, 16 rxns CATALOG # 1000190 QTY: 1 5) 5' Feature Barcode Kit, 16 rxns CATALOG # 1000256 QTY: 2 6) Dual Index Kit TT Set A 96 rxns CATALOG # 1000215 QTY: 1 7) Dual Index Kit TN Set A, 96 rxn CATALOG # 1000250 QTY: 1 8) Chromium Next GEM Single Cell 5' HT Kit v2, 48 rxns CAT# 1000356 QTY: 2 9) Chromium Next GEM Single Cell Multiome ATAC + Gene Expression Reagent Bundle, 16 rxns CATALOG # 1000283 QTY: 1 10) Chromium Next GEM Chip J Single Cell Kit, 48 rxns CATALOG # 1000234 QTY:1 11) Single Index Kit N Set A, 96 rxn CATALOG # 1000212 QTY: 1 12) Chromium X & Accessory Kit,12 Mo. Warranty 9/7/2022 CAT # 1000331 QTY: 1 13) Chromium Next GEM Single Cell HT Training Kit, 32 rxns CATALOG # 1000386 QTY:1 14) Shipping if applicable (FOB Destination) If offering an equal product, Country of Origin, place of manufactured products, must be provided with quote. If quoting an equal product you must show how the quoted equipment and consumables meets these qualifications: 1) Cell Analyzer must provide equal technology of the Chromium X model analyzer, powered by Next GEM Technology. 2) Equal products MUST provide a precisely engineered reagent delivery method that enables thousands of micro-reactions in parallel. 3) Equal products MUST confirm the ability to do the following: MUST be capable to Encapsulate a sample into hundreds to tens of thousands of uniquely addressable partitions in minutes, each containing an identifying barcode for downstream analysis. Each Gel Bead, infused with millions of barcoded oligonucleotides, is mixed with a sample, which can be individual cells or nuclei. Gel Beads and samples are then added to an oil-surfactant solution to create Gel Beads-in-Emulsion (GEMs), which act as individual reaction vesicles in which the Gel Beads are dissolved, and the sample is barcoded. Barcoded products are pooled for downstream reactions to create short-read sequencer compatible libraries. After sequencing, the resulting barcoded short read sequences are fed into turnkey analysis pipelines that use the barcode information to map reads back to their original single cell or single nucleus of origin. 4) All consumables Must be compatible with our Chromium brand controller units Unique Platform Characteristics - Generate single-cell transcript counts from up to 80,000 cells per run - Produce >90,000 individual nanoliter-scale partitions leveraging ~3.6 million unique barcodes - Capture cells at high efficiency up to 65% - Low doublet rate of 0.9% per 1,000 cells (~0.5% for HT) - Reveal clonality, diversity, antigen specificity, and cellular context - Assemble and annotate full-length V(D)J gene sequences - Pair ? and ? chain TCR sequences from individual T cells - Pair heavy and light chain immunoglobulin (Ig) sequences from individual B cells with full isotype resolution - Simultaneously measure TCR, B cell Ig, cell surface protein expression, and 5 gene expression in the same cells - Map full-length, paired T cell receptors with barcoded pMHC complexes - Map full-length, paired B cell receptors with barcoded antigens - Access the whole transcriptome with an unbiased approach appropriate for discovery work, or focus on a subset of relevant target genes by performing target enrichment of the same library sample prior to sequencing - Simultaneously measure cell surface protein expression with gene expression - Provide turn-key analysis pipelines and visualization software for novice and expert users alike - Include a microfluidics chip that is compatible with a wide range of eukaryotic cell sizes and types (e.g. adherent cell cultures, suspension cell cultures, tissues, blood, etc.) Place of Performance: The National Institutes of Health, Vaccine Research Center, 40 Convent Drive, Bethesda, MD 20814 United States. FOB: Destination The government intends to award a firm fixed price purchase order to the responsible contractor as a result of this RFQ that will include the terms and conditions set forth herein. The award will be based on the following: Technical capability to meet the brand name requirements, delivery date and price. The following FAR provisions apply to this acquisition: FAR 52.212-1 Instructions to Offerors Commercial Items (NOV 2021) FAR 52.212-3 Offerors Representations and Certifications - Commercial Items (MAY 2022) FAR 52.204-7 System for Award Management (OCT 2018) (Offerors must complete annual representations and certifications on-line at http://www.sam.gov/ in accordance with FAR 52.212-3 Offerors Representations and Certifications- Commercial Items (Please ensure 52.209-2 -- Prohibition on Contracting with Inverted Domestic Corporations--Representation. (Nov 2015) is updated in your SAM record) FAR 52.203-18 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements - Representation (JAN 2017) 52.204'26 Covered Telecommunications Equipment or Services-Representation (OCT 2020) *** Must complete representation if attached to this solicitation- see attachment 52.204-26 The following FAR contract clauses apply to this acquisition: FAR 52-212-4 Contract Terms and Conditions Commercial Items (NOV 2021) FAR 52-212.5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items (MAY 2022) *The applicable subparagraphs of FAR52.212-5 are included in the attachment to this posting. FAR 52.232-40 Providing Accelerated Payments to Small Business Subcontractors (NOV 2021) FAR 52.204-13 System for Award Management Maintenance (Oct 2018) FAR 52.204-25 Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment (NOV 2021) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 2015) 52.211-6 Brand Name or Equal. As prescribed in 11.107(a), insert the following provision: Brand Name or Equal (Aug 1999) (a) If an item in this solicitation is identified as "brand name or equal," the purchase description reflects the characteristics and level of quality that will satisfy the Government's needs. The salient physical, functional, or performance characteristics that "equal" products must meet are specified in the solicitation. (b) To be considered for award, offers of "equal" products, including "equal" products of the brand name manufacturer, must- (1) Meet the salient physical, functional, or performance characteristic specified in this solicitation; (2) Clearly identify the item by- (i) Brand name, if any; and (ii) Make or model number; (3) Include descriptive literature such as illustrations, drawings, or a clear reference to previously furnished descriptive data or information available to the Contracting Officer; and (4) Clearly describe any modifications the offeror plans to make in a product to make it conform to the solicitation requirements. Mark any descriptive material to clearly show the modifications. (c) The Contracting Officer will evaluate "equal" products on the basis of information furnished by the offeror or identified in the offer and reasonably available to the Contracting Officer. The Contracting Officer is not responsible for locating or obtaining any information not identified in the offer. (d) Unless the offeror clearly indicates in its offer that the product being offered is an "equal" product, the offeror shall provide the brand name product referenced in the solicitation. (End of provision) 52.252-2 -- Clauses Incorporated by Reference. (Feb 1998) This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this address: http://farsite.hill.af.mil/vffara.htm By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the System for Award Management (SAM) database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation (www.sam.gov). Copies of the above-referenced provisions and clauses are available from http://www.acquisition.gov/far/loadmainre.html & http: //www.hhs.gov/regulation/index.html or, upon request, either by telephone or fax. Submission shall be received not later than July 18, 2022 @ 4:00 pm Eastern Time. Offers may be mailed, e-mailed to Diana Rohlman; (E-Mail contact@example.gov). Offers shall include RFQ number in the subject line (RFQ-NIAID-2134590) Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f) All responsible sources may submit an offer that will be considered by this Agency. Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Diana Rohlman; contact@example.gov